Irofulven
From Wikipedia, the free encyclopedia
| Irofulven | |
|---|---|
| IUPAC name | (5'R)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethyl- spiro[cyclopropane-1,6'-indene]-4'-one |
| Identifiers | |
| CAS number | |
| PubChem | |
| SMILES | C[C@@]1(O)[C@]2(CC2)C(C)=C3C(C1=O)=CC(C)=C3CO |
| Properties | |
| Molecular formula | C15H18O3 |
| Molar mass | 246.302 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
|
Irofulven or 6-hydroxymethylacylfulvene (also known as HMAF of MGI-114) is a substance that is used in the treatment of cancer. It belongs to the family of drugs called alkylating agents.
Irofulven is an analogue of illudin S, a sesquiterpene toxin found in mushrooms of the genus Omphalotus. The compound was oringally synthesized by Dr. Trevor McMorris (UCSD) and found to have anticancer properties by Dr. Michael J Kelner (UCSD).[1]
[edit] References
- ^ MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD (1997). "Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S". Cancer Res. 57 (2): 279–83. PMID 9000568. Free full text
Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 14(2) 161-167, 1996

